KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard
KALA BIO received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price, violating a listing rule. The company is ineligible for the standard compliance period due to a recent reverse split and will request a hearing. The stock will remain listed pending the decision.
How this was made
The 30-second read
Why it matters
The Nasdaq staff determination triggers a hearing and may suspend trading, creating short‑term volatility.
Market read
Listing compliance issue could affect other micro‑cap biotech stocks and Nasdaq's enforcement perception.
What to watch
Potential for reverse split to stabilize price if compliance is achieved
Background
KALA BIO completed a 1‑for‑50 reverse split on May 11, 2026, but its share price fell below $1 for 30 consecutive days.
Ticker impact
Nasdaq staff determination that KALA BIO failed $1 bid price requirement after reverse split
Downward pressure if suspension occurs
Listing non‑compliance often leads to share price decline and liquidity risk
Market effects
May signal heightened compliance scrutiny for other low‑price biotech stocks
Limited to US Nasdaq micro‑cap segment
Low
Counterpoint
If hearing results in a waiver, stock could rebound sharply
Key entities
- Regulatory BodyNasdaq
Staff panel enforcing Listing Rule 5550(a)(2)
- CompanyKALA BIO, Inc.
Biotech firm facing delisting risk
